Gilead says its twice-yearly shot cut HIV infections by 96% in trial
The data sets the stage for likely approval of Gilead’s lenacapavir for HIV prevention.
—————
Boost Internet Speed–
Free Business Hosting–
Free Email Account–
Dropcatch–
Free Secure Email–
Secure Email–
Cheap VOIP Calls–
Free Hosting–
Boost Inflight Wifi–
Premium Domains–
Free Domains
